- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03626311
Omega-3 Replacement With Krill Oil in Disease Management of SLE (ORKIDS)
A Double-Blind, Placebo-Controlled Randomized, Multicenter Study to Assess Changes in Omega-3 Index in Erythrocytes and Health Benefit After 24 Weeks of Daily Consumption of AKBM-3031 (Omega-3 Phospholipids From Krill), Followed by a 24 Week Open-Label Extension, in Patients With Systemic Lupus Erythematosus (SLE)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Quebec, Canada
- University of Laval
-
-
British Columbia
-
Vancouver, British Columbia, Canada
- Lupus Clinic-Mary Pack Arthritis Centre
-
-
Ontario
-
Hamilton, Ontario, Canada
- McMaster University Medical Center
-
-
Quebec
-
Montréal, Quebec, Canada
- McGill University Health Centre-The Montreal General Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35249
- University of Alabama at Birmingham
-
-
California
-
Beverly Hills, California, United States, 90211
- Wallace Rheumatic Studies Center, LLC
-
Orange, California, United States, 92868
- UC Irvine Health
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush Medical Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Health System
-
-
Minnesota
-
Rochester, Minnesota, United States, 55902
- Mayo Clinic
-
-
New York
-
Bronx, New York, United States, 10461
- Albert Einstein College of Medicine
-
Great Neck, New York, United States, 11021
- Northwell Health
-
Manhasset, New York, United States, 11030
- Feinstein Institute for Medical Research
-
New York, New York, United States, 10021
- Hospital for Special Surgery
-
Rochester, New York, United States, 14642
- University of Rochester Medical Center
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest Baptist Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female aged at least 18 years old.
- Capable of giving written consent on an Institutional Review Board or IRB-approved Informed Consent Form prior to any study-specific evaluation
- Have a clinical diagnosis of SLE with at least 4 of the 11 American College of Rheumatology (ACR) criteria as modified in 1997 or meeting SLICC criteria
- SLE activity (SLEDAI ≥6)
On a stable SLE treatment regimen consisting of a stable dosage of any of the following medications for a period of at least 30 days prior to Baseline (i.e., day of 1st dose of study agent):
- Corticosteroids. Corticosteroids (< 20 mg prednisone or equivalent per day)
- Hydroxychloroquine or equivalent anti-malarial
- Other immunosuppressive or immunomodulatory agents including methotrexate, azathioprine, leflunomide, mycophenolate (including mycophenolate mofetil, mycophenolate mofetil hydrochloride, and mycophenolate sodium at no more than 2 grams/day), calcineurin inhibitors (e.g., tacrolimus,cyclosporine)
- Belimumab dose must be stable for 60 days prior to Baseline
- Cyclophosphamide dose must be stable for the last 90 days prior to Baseline
- Have not received rituximab within 6 months
- Have a low habitual consumption of fatty fish and seafood, defined as a frequency of twice per month or less; see Addendum 1 for a list of fish and seafood considered to be fatty.
Exclusion Criteria:
Patients are excluded from the study if any of the following criteria are met:
- Have rapidly progressive neurologic or renal disease
- Currently taking an omega-3 prescription drug (e.g. Lovaza®, Vascepa®, etc.) or as medical food (e.g. Vascazen®, Vayarin, Onemia™etc.)
- Present or recent use (within 3 months of screening) of any OTC fish or krill oil dietary supplement., or any long-chain omega-3 fatty acid dietary supplement (e.g.,MegaRed)
- Have severe lupus kidney disease (defined by proteinuria > 6 gm/24 hour or equivalent using spot urine protein to creatinine ratio, or serum creatinine > 2.5mg/dL)
- Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases not related to SLE (i.e., diabetes, cardiovascular, pulmonary, hematologic, gastrointestinal, neurological, or infectious) which, in the opinion of the treating physician, could confound the results of the study or put the patients at undue risk
- Have received intravenous glucocorticoids at a dosage of ≥ 500 mg daily within the past month
- Require anti-coagulation with coumadin, clopidogrel, dalteparin, dypyridamole, enoxaparin, heparin or ticlopidine. Low dose aspirin (<325 mg/day) is permitted.
- Receiving orlistat (Xenical, Alli) and have refused to discontinue at baseline and throughout the trial.
- History of allergy to seafood or shellfish
- Have current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within 364 days prior to Baseline
- Are pregnant or lactating
- Recent participation in a clinical trial with an experimental agent in the past 6 weeks, or 5 half-lives of the study drug, whichever is longer
Have a Grade 3 or greater laboratory abnormality based on the Adverse Event Severity Grading Tables (CTCAE), except for the following that are allowed:
- Stable Grade 3 partial thromboplastin time (PTT) due to lupus anticoagulant and not related to liver disease or anti-coagulant therapy
- Stable Grade 3 hypoalbuminemia due to chronic lupus nephritis, and not related to liver disease
- Stable Grade 3 gamma glutamyl transferase (GGT) elevation due to lupus hepatitis, and not related to alcoholic liver disease, uncontrolled diabetes, or viral hepatitis. If present, any abnormalities in the ALT or Alanine Transaminase and/or AST or Aspartate Transaminase must be < Grade 2.
- Stable Grade 3 neutropenia or stable Grade 3 white blood cell count due to lupus.
Patients will be excluded from the study based on the following bone marrow, hepatic and renal function values:
- Hemoglobin: < 8.0 gm/dL
- Platelets: <50,000/mm
- ANC < 1.0 x 103/mm
- AST or ALT >2.5 x Upper Limit of Normal unless related to primary disease.
- Creatinine clearance ≤ 25ml/min per 1.73m2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: AKBM-3031
4g/day (2 capsules BID)
|
Krill are shrimp-like small crustaceans (up to 6 cm) found in all the world's oceans, but mostly in the Arctic and Antarctic polar seas. Krill are rich in the long-chain omega-3 polyunsaturated fatty acids or LC-PUFAs eicosapentaenoic acid (EPA, C20:5n3) and docosahexaenoic acid (DHA, C22:6n3). The lipid pool of krill is composed of phospholipids and triglycerides and the LC-PUFAs are primarily in the phospholipid fraction. The product is produced under food Good Manufacturing Practice (GMP) regulations and has status as GRAS or Generally Recognized As Safe. GRAS is defined by the US Food and Drug Administration (FDA) as a substance that is generally recognized, among qualified experts, to be safe under the conditions of its intended use.
Other Names:
|
PLACEBO_COMPARATOR: Placebo
4g/day (2 capsules BID)
|
The placebo will be provided in capsules looking exactly as the krill oil capsules and will contain a fatty acid mixture (olive oil, corn oil, palm oil and medium chain triglycerides) which has the same composition as the average European diet (26.0%
C16:0, 4.6% C18:0, 35.8% C18:1n9, 16.7% C18:2n6, 2.1% C18:3n3, 0% C20:4n6 and 14.8% other compounds) and contains no EPA or DHA.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in the ratio of omega-3 to omega-6 measured through lab tests on red blood cells from baseline through the end of the study in patients with generalized lupus.
Time Frame: Baseline to 24 weeks
|
Baseline to 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of correction of omega-3 deficiency measured by SLE biomarkers of immune function.
Time Frame: Baseline to 24 weeks
|
Baseline to 24 weeks
|
|
Effect of correction of omega-3 deficiency measured by both clinician and patient reported outcomes collected at clinic visits.
Time Frame: Baseline to 24 weeks
|
Baseline to 24 weeks
|
|
Change in health related quality of life measured using the Medical Outcomes study Short Form 36 (SF-36).
Time Frame: Baseline to 24 weeks
|
Both physical component scores (PCS) and mental component scores (MCS) will be assessed.
Change in both PCS and MCS will be evaluated over the time of this study.
The SF-36 is a patient recorded survey of health related quality of life, consisting of the evaluation of 8 domains, and then scored from 0-100.
The higher score correlates to better health-related quality of life.
The mean for healthy individuals is 50.
|
Baseline to 24 weeks
|
Difference of number of patients with reported adverse events or changes in lab parameters while taking AKBM-3031.
Time Frame: Baseline to 24 weeks
|
Examples of patient reported adverse events include gastrointestinal symptoms, infection, unexplained bleeding, etc. Examples of lab parameters indicating an adverse event are changes in liver function tests, urinalysis, and hematologic parameters (which could be considered an adverse event).
|
Baseline to 24 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMP-004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus (SLE)
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
Novartis PharmaceuticalsNot yet recruitingSystemic Lupus Erythematosus, SLE
-
Changhai HospitalRui Therapeutics Co., LtdRecruitingSystemic Lupus Erythematosus (SLE)China
-
Bioray LaboratoriesFirst Affiliated Hospital of Zhejiang UniversityRecruitingSystemic Lupus Erythematosus (SLE)China
-
Sohag UniversityNot yet recruitingSystemic Lupus Erythematosus (SLE)
-
AbbVieCompletedSystemic Lupus Erythematosus (SLE)United States, Argentina, Australia, Bulgaria, China, Colombia, Germany, Hungary, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Puerto Rico, Spain, Taiwan, United Kingdom
-
BiogenEnrolling by invitationSystemic Lupus Erythematosus (SLE)United States, China, Belgium, Korea, Republic of, Netherlands, Spain, Greece, Australia, Italy, Bulgaria, Hungary, France, Serbia, Argentina, Mexico, Brazil, Poland, Taiwan, Germany, Philippines, Sweden, Czechia, Chile, Russian Federation and more
Clinical Trials on AKBM-3031
-
Dong-A ST Co., Ltd.CompletedLymphoma | Solid TumorKorea, Republic of
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
Sorrento Therapeutics, Inc.WithdrawnDiffuse Large B Cell Lymphoma | Biliary Tract Cancer | Peripheral T Cell Lymphoma | Extranodal NK T Cell Lymphoma, Nasal
-
Dong-A ST Co., Ltd.CompletedHealthy VolunteersKorea, Republic of
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMelanoma | Metastatic Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Metastatic MelanomaUnited States
-
Dong-A ST Co., Ltd.CompletedChemotherapy Induced NeutropeniaKorea, Republic of
-
Dong-A ST Co., Ltd.CompletedChemotherapy Induced NeutropeniaKorea, Republic of
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable MelanomaUnited States